**Appendix**

**Supporting information for: “Variability of cost trajectories over the last year of life in patients with advanced breast cancer in the Netherlands”**

|  |
| --- |
| **S1 Table: Unit costs (in €2017)**  |
| **Resource** | **Unit cost** | **Ref** | **Resource** | **Unit cost** | **Ref** |
| 5-fluorouracil | 0.0067 | 3 | Docetaxel | 5.04 | 3 |
| Abdominal surgery | Confidential | 2 | Doxorubicin | 22.02 | 3 |
| Ablatio with reconstruction | Confidential | 2 | Drainage of ureter | Confidential | 2 |
| Alendronic acid | 0.01 | 3 | Drug administration | 130.00 | 4 |
| Anastrozol | 0.03 | 3 | Echocardiography | 78.78 | 1 |
| Ascites drainage | 143.24 | 1 | Emergency Dep. visit | 263.40 | 1 |
| Axillary node dissection | Confidential | 2 | Epirubicine | 6.15 | 3 |
| Bevacizumab | 3.37 | 3 | Eribulin | 480.19 | 3 |
| Biopsy | Confidential | 2 | Erythrocytes transfusion | 219.67 | 1 |
| Bone scan | Confidential | 2 | ER-test | 47.40 | 5 |
| Brain/neurosurgery | Confidential | 2 | Etoposide | 0.17 | 3 |
| Brivanib | 1.00 | 3 | Everolimus | 14.58 | 3 |
| CA 15.3 | Confidential | 2 | Exemestane | 0.0092 | 3 |
| Capecitabin | 0.0027 | 3 | Fulvestrant | 1.30 | 3 |
| Carboplatin | 0.31 | 3 | Gemcitabin | 0.09 | 3 |
| Central venous catheter | Confidential | 2 | Gosereline | 340.58 | 3 |
| Clodronic acid | 0.0041 | 3 | HER2 FISH test | 148.13 | 5 |
| CT abdomen | 192.35 | 1 | HER2 IHC | 47.40 | 5 |
| CT other | 131.98 | 1 | Hickmann | Confidential | 2 |
| CT thorax | 185.19 | 1 | Ibandronic acid | 0.11 | 3 |
| CT thorax abdomen | 377.54 | 1 | ICU in-patient day | 1,206.16 | 1 |
| Cyclophosphamide | 0.03 | 3 | In-patient day | 646.81 | 1 |
| Cytarabine | 1.33 | 3 | Lapatinib | 0.07 | 3 |
| Denosumab | 3.58 | 3 | Letrozole | 0.02 | 3 |
| DEXA Bone Densitometry | 78.78 | 1 | Liver surgery | Confidential | 2 |
| **Table S1 (continued): Unit costs (in 2017 €)**  |
| **Resource** | **Unit cost** | **Ref** | **Resource** | **Unit cost** | **Ref** |
| Lumpectomy | Confidential | 2 | Port a cath | Confidential | 2 |
| Mamma sono | 89.01 | 1 | PR-test | 47.40 | 5 |
| Mastectomy | Confidential | 2 | Pulmonary surgery | Confidential | 2 |
| Medroxyprogesteron | 0.0051 | 3 | Radiotherapy | 252.81 | 6 |
| Megestrol | 0.02 | 3 | Resection metastasis (other) | Confidential | 2 |
| Methotrexate | 0.23 | 3 | Resection of skin metastasis | Confidential | 2 |
| Mitomycin | 3.86 | 3 | Risedronic acid | 0.02 | 3 |
| MRI | 257.83 | 1 | Secondary reconstruction | Confidential | 2 |
| MUGA scan | 78.78 | 1 | Sentinel node procedure | Confidential | 2 |
| Olaparib | 0.24 | 3 | Stent bile duct | Confidential | 2 |
| Orthopedic surgery: extremities | Confidential | 2 | Stent gastro-intestinal tract | Confidential | 2 |
| Orthopedic surgery: spine | Confidential | 2 | Surgery contralateral axilla | Confidential | 2 |
| Paclitaxel | 2.49 | 3 | Surgery of nodes (outside) | Confidential | 2 |
| Palbociclib | 1.64 | 3 | T-DM1 | 18.66 | 3 |
| Pamidronic acid | 2.02 | 3 | Tamoxifen | 0.01 | 3 |
| Pertuzumab | 0.17 | 3 | Telephone consultation | 17.29 | 1 |
| PET and MRI Scan | Confidential | 2 | Thrombocytes transfusion | 530.87 | 1 |
| PET low dose | Confidential | 2 | Trastuzumab | 4.02 | 3 |
| PET normal | Confidential | 2 | Vinorelbin | 2.45 | 3 |
| PICC catheter | Confidential | 2 | X-ray | Confidential | 2 |
| Pleura drainage | 143.24 | 1 | Zoledronic acid | 34.98 | 3 |
| Policlinic visit | 134.24 | 1 |  |  |  |
| 1 | Ref: Institute for Medical Technology Assessment. BIJLAGE 1 Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. Erasmus Universiteit Rotterdam. 2016. |
| 2 | Maastricht University Medical Centre+. Internal cost prices. 2018. Confidential |
| 3 | Zorginstituut Nederland. Medicijnkosten. 2018. Available at: https://www.medicijnkosten.nl/ |
| 4 | Franken MF, Kanters T, Uyl-de Groot C. Insights into healthcare and societal costs of subcutaneous injection and intravenous infusion of trastuzumab for HER2 positive breast cancer and rituximab for non-Hodgkin’s lymphoma in The Netherlands. 2017. Available at: https://www.imta.nl/assets/uploads/2017/12/Abstract-IMTA\_2017\_1205.pdf |
| 5 | Essers BA, Seferina SC, Tjan‐Heijnen VC, Severens JL, Novák A, Pompen M, Oron UH, Joore MA. Transferability of model‐based economic evaluations: the case of trastuzumab for the adjuvant treatment of HER2‐positive early breast cancer in the Netherlands. Value in health. 2010 Jun 1;13(4):375-80. doi: 10.1111/j.1524-4733.2009.00683.x |
| 6 | Timmer-Bonte, JN, Adang, EM, Smit, HJ et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol. 2006; 24: 2991–2997 |